| Issue Type | XXXX |
|---|---|
| Country | Belgium |
| Industry | XXXX |
| Region | XXXX |
| Maturity Date | 2030-03-20 |
| Par Value | 100000 |
| Callable | XXXX |
| Next Call Date | XXXX |
| Call Type | XXXX |
| Call Price (%) | XXXX |
| Series | XXXX |
| Class | XXXX |
| Maturity Structure | XXXX |
| Amount Outstanding (mil) | 500.00 |
| Coupon | 4.25 |
|---|---|
| Coupon Type | XXXX |
| Coupon Frequency | XXXX |
| First Coupon Date | XXXX |
| Last Coupon Date | XXXX |
| Sinking Fund | XXXX |
|---|---|
| Security | XXXX |
| Subordination | XXXX |
| Debt Type | XXXX |
| Issue Date | XXXX |
|---|---|
| Dated Date | XXXX |
| Issue Size (mil) | 500 |
| Min. Piece | XXXX |
| Min. Increment | XXXX |
This UCB SA corporate medium term notes has a X.X % fixed rate coupon paid on a XXXX basis. It was issued on MAR 12, 2000 with an issue size of XXX million EUR and matures on DEC 9, 2000 with a last coupon date of FEB 28, 2020. |
UCB SA, founded in 1928 and headquartered in Brussels, Belgium, is a global biopharmaceutical company focused on the discovery and development of innovative medicines for severe diseases, particularly in neurology and immunology. The company specializes in therapies for conditions such as epilepsy, multiple sclerosis, and Crohn's disease, positioning itself as a key player in the pharmaceutical industry.